Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent
Composition comprises at least one Cdc25 phosphatase inhibitor (I) in combination with at least one other anticancer agent (II), for simultaneous, separate or successive use in the treatment of cancer. ACTIVITY : Cytostatic. In tests for inhibition of proliferation of HT-29 (human colon cancer) cell...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Composition comprises at least one Cdc25 phosphatase inhibitor (I) in combination with at least one other anticancer agent (II), for simultaneous, separate or successive use in the treatment of cancer. ACTIVITY : Cytostatic. In tests for inhibition of proliferation of HT-29 (human colon cancer) cells in vitro, the degree of cell survival after 6 days was 36% in presence of 1 MicroM 5-((2-(dimethylamino)-ethyl)-amino)-2-methyl-1,3-benzothiazole-4,7-dione (Ia) (as the hydrochloride), 44% in presence of 50 MicroM roscovitine (IIa) and 0% in presence of a combination of 1 MicroM (Ia) and 50 MicroM (IIa). MECHANISM OF ACTION : Cdc25 phosphatase inhibitor.
L'invention a pour objet un produit comprenant au moins un inhibiteur de phosphatase Cdc25 en association avec au moins un autre agent anti-cancéreux pour une utilisation thérapeutique simultané, séparée ou étalée dans le temps dans le traitement du cancer et où l'agent anti-cancéreux associé à l'inhibiteur de phosphatase Cdc25 est un inhibiteur des kinases dépendantes des cyclines (CDKs). |
---|